| Trial ID: | L3703 |
| Source ID: | NCT01002768
|
| Associated Drug: |
Insulin Degludec
|
| Title: |
Comparison of Hypoglycaemic Response Between NN1250 and Insulin Glargine in Type 1 Diabetics
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 1
|
| Interventions: |
DRUG: insulin degludec|DRUG: insulin glargine
|
| Outcome Measures: |
Primary: Baseline-adjusted hypoglycaemic symptoms score at nadir plasma glucose concentration, Within 0-46 hours after last trial product administration | Secondary: Baseline-adjusted hypoglycaemic symptoms score at each level of plasma glucose, Within 0-46 hours after last trial product administration|Time from start of hypoglycaemic induction until each level of plasma glucose is reached, Within 0-46 hours after last trial product administration|Time to increase from nadir plasma glucose to a plasma glucose concentration of 3.9 mmol/L, Within 0-46 hours after last trial product administration|Hypoglycaemic symptoms score during recovery from hypoglycaemia, Within 0-46 hours after last trial product administration
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
28
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2009-10
|
| Completion Date: |
2010-03
|
| Results First Posted: |
|
| Last Update Posted: |
2017-01-20
|
| Locations: |
Novo Nordisk Investigational Site, Graz, 8010, Austria
|
| URL: |
https://clinicaltrials.gov/show/NCT01002768
|
